• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign in
SUBSCRIBE
2 Minute Medicine
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Gastroenterology

Proguanil and atovaquone use may be associated with lower colorectal cancer risk

byDavy LauandAlex Chan
November 14, 2022
in Gastroenterology, Surgery
Reading Time: 2 mins read
Development of a risk index for colorectal cancer screening
Share on FacebookShare on Twitter

1. The use of proguanil/atovaquone amongst individuals with a family history of colorectal cancer (CRC) was associated with a decreased risk of developing CRC.

Evidence Rating Level: 2 (Good)

Individuals who have relatives with colorectal cancer (CRC) have a 2-4 times increased lifetime risk of developing CRC, compared to those with negative family history. Therefore, preventative strategies for CRC have been explored, including drug repositioning. One class of drug that has been proposed is biguanides, known to have anti-proliferative properties, with the drug proguanil found to have the most inhibitory action against colon cancer cells compared to other biguanides. As well, the drug atovaquone was also found to exert anti-cancer activity through inhibiting mitochondrial production of oxygen radicals. Together, proguanil/atovaquone is used as an anti-malarial drug. Therefore, this retrospective cohort study based in Sweden examined the correlation between proguanil/atovaquone exposure with CRC risk, for individuals with CRC in their family history. Health records were accessed from 2005 to 2018, the end of the study period. Every patient that was prescribed proguanil/atovaquone was matched to 10 randomly selected comparisons based on age and sex. In total, 184,987 patients were found to have a first-degree relative diagnosed with CRC. With a mean follow-up of 7.1 years, the study found that the incidence of CRC amongst proguanil/atovaquone exposed individuals was lower than non-users, with 9.32 compared to 12.07 per 10,000 person-years, with an adjusted hazards ratio of 0.76 (95% CI 0.62-0.93). This relationship was also found to be dose-dependent and duration-dependent (p < 0.001). As well, the correlation was greater for more advanced stages of CRC (adjusted HR 0.69, 95% CI 0.51-0.92) as opposed to earlier stages (adjusted HR 0.88, 95% CI 0.65-1.20). Overall, this study showed that the use of proguanil/atovaquone amongst individuals with family history of CRC was associated with a decreased incidence of developing CRC.

Click to read the study in BMC Medicine

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

Male sex is associated with higher mortality among patients with hepatocellular carcinoma

Daraxonrasib extends survival in metastatic pancreatic cancer

Molecularly guided therapy may improve outcomes in patients with unfavourable cancer of unknown primary compared with standard chemotherapy

Tags: colorectal canceroncology
Previous Post

Oxygenation targets do not alter outcomes in critically ill patients

Next Post

Modifying advertising and nutrition labels helps reduce parental purchase of high-sugar beverages

RelatedReports

Chronic Disease

Male sex is associated with higher mortality among patients with hepatocellular carcinoma

October 7, 2026
Oncology

Daraxonrasib extends survival in metastatic pancreatic cancer

September 17, 2026
Quick Take: Diagnostic Yield of One-Time Colonoscopy vs One-Time Flexible Sigmoidoscopy vs Multiple Rounds of Mailed Fecal Immunohistochemical Tests in Colorectal Cancer Screening
Chronic Disease

Molecularly guided therapy may improve outcomes in patients with unfavourable cancer of unknown primary compared with standard chemotherapy

September 7, 2026
Long-term outcomes for off-pump and on-pump CABG are similar
Weekly Rewinds

2 Minute Medicine Rewind September 7, 2026

September 7, 2026
Next Post
Parent mentors are effective at insuring uninsured children

Modifying advertising and nutrition labels helps reduce parental purchase of high-sugar beverages

The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!

The Scan by 2 Minute Medicine®: An Organ Donor Crisis, A Closer Look at Bipolar Disorder, What to know about Processed Foods, and Key Issues in Men's Health

Rapid genetic testing useful for diagnosis of critically ill children

Parenteral amino acids do not improve outcomes for low-birth-weight infants

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Gepotidacin (Blujepa) is safe and effective in women with uncomplicated urinary tract infections
  • Most routine blood tests do not require prolonged fasting
  • Pairing cardiac magnetic resonance with electrocardiograms (ECGs) improved artificial intelligence (AI) assessments of cardiovascular diseases
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.